NCT02187848 - Evaluation of SAR408701 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

254

Participants

Timeline

Start Date

July 23, 2014

Primary Completion Date

November 10, 2020

Study Completion Date

November 19, 2024

Conditions

Neoplasm Malignant

Interventions

DRUG

SAR408701

Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

Trial Locations (20)

13385

Investigational Site Number : 250004, Marseille

21079

Investigational Site Number : 250006, Dijon

28040

Investigational Site Number : 724004, Madrid / Madrid

28041

Investigational Site Number : 724006, Madrid

28050

Investigational Site Number : 724003, Madrid

28222

Investigational Site Number : 724002, Majadahonda

31059

Investigational Site Number : 250002, Toulouse

33076

Investigational Site Number : 250003, Bordeaux

35000

Investigational Site Number : 250007, Rennes

94163

Investigational Site Number : 250005, Saint-Mandé

94800

Investigational Site Number : 250001, Villejuif

06520-8017

Yale University School of Medicine Site Number : 840002, New Haven

02115

Dana Farber Cancer Institute- Site Number : 840005, Boston

M5G 2M9

Investigational Site Number : 124001, Toronto

03080

Investigational Site Number : 410002, Seoul

03722

Investigational Site Number : 410005, Seoul

06351

Investigational Site Number : 410003, Seoul

07061

Investigational Site Number : 410004, Seoul

138-736

Investigational Site Number : 410001, Seoul

08035

Investigational Site Number : 724001, Barcelona